Episode Details

We sit down with Rafiq Hasan, co-founder & CEO of Complement Therapeutics, at their London offices to unpack a milestone-loaded past 6 months.

Rafiq shares the company's thesis, based on research from Manchester university, and how in practice they are targeting the complement system.

We also dig into a landmark moment for the company - the recent dosing of patients in OPTI-GAIN, their Phase 1/2 clinical trial targeting Geographic Atrophy, a leading cause of irreversible vision loss.

Another topic of discussion centers around what it's took to build a biotech from the ground up over the past few challenging years.

Definitely worth a listen for anyone building in ophthalmology, gene therapy, or across UK biotech.